Acute demyelinating optic neuritis

Expert Review of Ophthalmology

Volumn 1, Issue 2, 2006, Pages 159-170

  Burkholder, Bryn M ^a   Galetta, Steven L ^a   Balcer, Laura J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

demyelinating; Interferon b 1a; Interferon 1 ; magnetic resonance imaging; methylprednisolone; multiple sclerosis; optic neuritis; optic neuropathy; optical coherence tomography

Indexed keywords

EID: 78650706391     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.1.2.159     Document Type: Article

References (78)

1. Beck RW. The Optic Neuritis Treatment Trial. Arch. Ophthalmol. 106, 1051–1053 (1988).
2. Optic Neuritis Study Group. The clinical profile of acute optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch. Ophthalmol. 109, 1673–1678 (1991).
3. Beck RW, Cleary PA, Anderson MA et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N. Engl. J. Med. 326, 581–588 (1992).
4. Liu GT. Visual loss. optic neuropathies. In: Neuro-Ophthalmology: Diagnosis and Management. Liu GT, Volpe NJ, Galetta SL (Eds), WB Saunders, PA, USA 103–187 (2000).
5. Kaufman DI, Trobe JD, Eggenberger ER, Whitaker JN. Practice parameter. the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54, 2039–2044 (2000).
6. Balcer LJ, Galetta SL. Optic neuritis. In: Conn’s current therapy. Rakel RE, Bope ET (Eds.), WB Saunders, PA, USA 187–190 (2004).
7. Balcer LJ. Optic Neuritis. N. Engl. J. Med. 354, 43–50 (2006).
8. Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am. J. Ophthalmol. 139, 1101–1108 (2005).
9. Atkins EJ, Biousse V, Newman NJ. The Natural History of Optic Neuritis. Rev. Neurol.l Dis. 3, 45–56 (2006).
10. Newman NJ, Biousse V. Hereditary optic neuropathies. Eye 18, 114–160 (2004).
11. Wakakura M, Minei-Higa R, Oono S et al. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Jpn J. Ophthalmol. 43, 127–132 (1999).
12. Wakakura M, Mashimo K, Oono S et al. Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Jpn J. Ophthalmol. 43, 133–138 (1999).
13. Beck RW, Cleary PA, Trobe JD et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of MS. N. Engl. J. Med. 329, 1764–1769 (1993).
14. Beck RW, Optic Neuritis Study Group. Corticosteroid treatment of optic neuritis. a need to change treatment practices. Neurology 42, 1133–1135 (1992).
15. Beck RW, Kupersmith MJ, Cleary PA et al. Fellow eye abnormalities in acute unilateral optic neuritis: experience of the Optic Neuritis Treatment Trial. Ophthalmology 100, 691–698 (1993).
16. Beck RW, Arrington J, Murtagh FR, et al. Brain MRI in acute optic neuritis: experience of the Optic Neuritis Study Group. Arch. Neurol. 8, 841–846 (1993).
17. Optic Neuritis Study Group. The five-year risk of MS after optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology 49, 1404–1413 (1997).
18. Keltner JL, Johnson CA, Spurr JO et al. Baseline visual field profile of optic neuritis: the experience of the Optic Neuritis Treatment Trial. Arch. Ophthalmol. 111, 231–234 (1993).
19. Beck RW, Cleary PA, Backlund J et al. The course of visual recovery after optic neuritis: experience of the Optic Neuritis Treatment Trial. Ophthalmology 101, 1171–1178 (1994).
20. Trobe JD, Beck RW, Moke PS, Cleary PA. Contrast sensitivity and other vision tests in the Optic Neuritis Treatment Trial. Am. J. Ophthalmol. 121, 547–553 (1996).
21. The Optic Neuritis Study Group. Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch. Ophthalmol. 115, 1545–1552 (1997).
22. Keltner JL, Johnson CA, Spurr JO, Beck RW, for the Optic Neuritis Study Group. Comparison of central and peripheral visual field properties in the Optic Neuritis Treatment Trial. Am. J. Ophthalmol. 128, 543–553 (1999).
23. Fang JP, Donahue SP, Lin RH. Global visual field involvement in acute unilateral optic neuritis. Am. J. Ophthalmol. 128, 554–565 (1999).
24. Fang JP, Lin RH, Donahue SP. Recovery of visual field function in the Optic Neuritis Treatment Trial. Am. J. Ophthalmol. 128, 566–572 (1999).
25. Arnold AC. Visual field defects in the Optic Neuritis Treatment Trial: central vs peripheral, focal vs global. Am. J. Ophthalmol. 128, 632–634 (1999).
26. Cleary PA, Beck RW, Bourque LB, Backlund JC, Miskala PH, for the Optic Neuritis Study Group. Visual symptoms after optic neuritis: results from the Optic Neuritis Treatment Trial. J. Neuroophthalmol. 17, 18–28 (1997).
27. Cole SR, Beck RW, Moke PS, Gal RL, Long DT, and the Optic Neuritis Study Group. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Invest. Ophthalmol. Vis. Sci. 41, 1017–1021 (2000).
28. Trobe JD, Sieving PC, Guire KE, Fendrick AM. The impact of the Optic Neuritis Treatment Trial on the practices of ophthalmologists and neurologists. Ophthalmology 106, 2047–2053 (1999).
29. Beck RW, Trobe JD, Moke PS et al. High- and low-risk profiles for the development of MS within 10 years after optic neuritis. Arch. Ophthalmol. 121, 944–949 (2003).
30. Beck RW, Optic Neuritis Study Group. The Optic Neuritis Treatment Trial: implications for clinical practice. Arch. Ophthalmol. 110, 331–332 (1992).
31. Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis. experience of the optic neuritis treatment trial. Am. J. Ophthalmol. 137, 77–83 (2004).
32. de la Cruz J, Kupersmith MJ. Clinical profile of simultaneous bilateral optic neuritis in adults. Br. J. Ophthalmol. 90, 551–554 (2006).
33. Frisen L, Hoyt WF. Insidious atrophy of retinal nerve fibers in multiple sclerosis. funduscopic identification in patients with and without visual complaints. Arch. Ophthalmol. 92, 91–97 (1974).
34. Balcer LJ, Baier ML, Pelak VS et al. New low-contrast vision charts. reliability and test characteristics in patients with MS. Mult. Scler. 6, 163–171 (2000).
35. Cole SR, Beck RW, Moke PS et al. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Neurology 51, 885–887 (1998).
36. Masjuan J, Alvarez-Cermeno JC, Garcia-Barragan N et al. Clinically isolated syndromes. A new oligoclonal band test accurately predicts conversion to MS. Neurology 66, 576–578 (2006).
37. Balcer LJ. MS and related demyelinating diseases. In: Walsh & Hoyt’s Clinical Neuro-ophthalmology, Vol. 3, 6th Edition. Miller NR, Newman NJ, Biousse V, Kerrison JB (Eds), Lippincott, Williams & Wilkins, PA, USA 3429–3525 (2005).
38. Fraser CL, Klistorner A, Graham SL, Garrick R, Billson FA, Grigg JR. Multifocal visual evoked potential analysis of inflammatory or demyelinating optic neuritis. Ophthalmology 113, 315–323 (2006).
39. Polman CH, Reingold SC, Edan G et al. Diagnostic Criteria for MS. 2005 Revisions to the McDonald Criteria. Ann. Neurol. 58, 840–846 (2005).
40. Fraser C, Klistorner A, Graham S, Garrick R, Billson F, Grigg J. Multifocal visual evoked potential latency analysis. predicting progression to multiple sclerosis. Arch. Neurol. 63, 847–850 (2006).
41. Trip SA, Wheeler-Kingshott C, Jones SJ et al. Optic nerve diffusion tensor imaging in optic neuritis. Neuroimage 30, 498–505 (2006).
42. Hickman SJ, Wheeler-Kingshott CA, Jones SJ et al. Optic nerve diffusion measurement from diffusion-weighted imaging in optic neuritis. Am. J. Neuroradiol. 26, 951–956 (2005).
43. Frohman EM, Frohman TC, Zee DS et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 4, 111–121 (2005).
44. Trapp BD, Peterson J, Ransohoff RM et al. Axonal transaction in the lesions of multiple sclerosis. N Engl J 338, 278–285 (1998).
45. Costello F, Coupland S, Hodge W et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann. Neurol. 59, 963–969 (2006).
46. Sergott RP, Piette S, Etter J, Savino P. In vivo neuroprotection with high-dose, high-frequency interferon therapy. A serial optical coherence tomography study in multiple sclerosis and optic neuritis. Proceedings of the 21st Congress of the European Committee for the Treatment and Research in Multiple Sclerosis. Thessaloniki, Greece, September 28–October 1 2005.
47. Trip SA, Schlottmann PG, Jones SJ et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann. Neurol. 58, 383–391 (2005).
48. Fisher JB, Jacobs DA, Markowitz CE et al. Relation of visual function to retinal nerve fiber layer thickness in MS. Ophthalmology 113, 324–332 (2006).
49. Rebolleda G, Munoz-Negrete FJ, Noval S, Contreras I, Gilbert ME, Sergott RC. New ways to look at an old problem. Surv. Ophthalmol. 51, 169–173 (2006).
50. Drug Topics Red Book. Thomson PDR, Montvale, NJ, USA (2005).
51. Jacobs LD, Cookfair D, Rudick RA et al. Intramuscular interferon β-1a for disease progression in relapsing MS. Ann. Neurol. 39, 285–294 (1996).
52. Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon β -1a therapy initiated during a first demyelinating event in MS. N. Engl. J. Med. 343, 898–904 (2000).
53. CHAMPS Study Group. Interferon β-1a for optic neuritis patients at high risk for MS. Am. J. Ophthalmol. 132, 463–471 (2001).
54. Kinkel RP, Kollman C, O’Connor P et al. IM Interferon β-1a delays definite MS 5 years after a first demyelinating event. Neurology 66, 678–684 (2006).
55. Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite MS. a randomized study. Lancet 357, 1576–1582 (2001).
56. Filippi M, Rovaris M, Inglese M et al. Interferon β-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis. A randomised, double-blind, placebo-controlled trial. Lancet 364, 1489–96 (2004).
57. Kappos L, Polman CH, Freedman MS et al. Treatment with interferon β-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67, 1242–1249 (2006).
58. Pittock SJ, Weinshenker BG, Noseworthy JH et al. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch. Neurol. 63, 611–614 (2006).
59. Frohman EM, Havrdova E, Lublin F et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch. Neurol. 63, 614–619 (2006).
60. Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe optic neuritis. Neurology 63, 1081–1083 (2004).
61. Van Engelen BGM, Hommes OR, Pinkers A et al. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis (letter). Ann. Neurol. 32, 834–835 (1992).
62. Roed HG, Langkilde A, Sellebjerg F et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 64, 804–810 (2005).
63. Noseworthy JH, O’Brien PC, Petterson TM et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56, 1514–1522 (2001).
64. Achiron A, Kishner I, Sarova-Pinhas I et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis. Arch. Neurol. 61, 1515–1520 (2004).
65. Brady KM, Brar AS, Lee AG et al. Optic neuritis in children: clinical features and visual outcome. J. AAPOS 3, 98–103 (1999).
66. Lucchinetti CF, Kiers L, O’Duffy A et al. Risk factors for developing MS after childhood optic neuritis. Neurology 49, 1413–1418, 1997.
67. Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology 67, 258–262 (2006).
68. Galetta SL, Bennett J. Neuromyelitis Optica is a variant of multiple sclerosis. Arch. Neurol. (In press).
69. Filippi M, Rocca MA. MR imaging of Devic’s neuromyelitis optica. Neurol. Sci. 25, 371–373 (2004).
70. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch. Neurol. 63, 390–396 (2006).
71. Lennon VA, Wingerchuck DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica. distinction from multiple sclerosis. Lancet 364, 2106–2112 (2005).
72. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 66, 1485–1489 (2006).
73. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202, 473–477 (2005).
74. Mandel RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica. a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51, 1219–1220 (1998).
75. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64, 1270–1272 (2005).
76. Brex PA, Miszkiel KA, O’Riordan JI et al. Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes. the role of follow-up MRI. J. Neurol. Neurosurg. Psychiatry 70, 390–393 (2001).
77. Schmalfuss IM, Dean CW, Sistrom C, Bhatti MT. Optic neuropathy secondary to cat scratch disease: distinguishing MR imaging features from other types of optic neuropathies. Am. J. Neuroradiol. 26, 1310–1316 (2005).
78. Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA 273, 625–632 (1995).